Validation of a Predictive Risk Equation for Type 2 Diabetes in Families With Risk (DESCENDANCE)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Considering its epidemic-like development worldwide, associated with modifications in lifestyle, as well as its enormous social and economic weight, the prevention of type II diabetes is certain to be a central concern of health systems within the developed countries in the decades to come. However, while simple obesity concerns the entire population, type 2 diabetes affects only one sub-population at high genetic risk. To be effective and realistic in economic terms, efforts at prevention must be thus targeted towards these subjects at high risk. The key issue involves identifying such subjects early enough so that a strategy of effective prevention can be organized in good time.
Until now, efforts have been concentrated on individuals at risk for diabetes readily identifiable within the general population, typically subjects in the second half of adulthood, presenting abdominal obesity and mild abnormalities of blood sugar. Preventive lifestyle and dietary measures are proposed but are constrictive and difficult to maintain over time, and the results, although they may be significant, remain disappointing, with mere postponement of an outcome which at this stage appears inevitable. The reason is ascribable to excessively tardy intervention, when the pathogenic process has already been ongoing for some ten years and the endocrine function of the pancreas is probably already irreparably impaired.
The alternative thus is earlier intervention, in childhood, adolescence or early adulthood. The problem is to identify individuals at high risk of becoming diabetic at a time when they are presenting no simple clinical or laboratory abnormalities allowing easy diagnosis. The familial character of type 2 diabetes is now well established, and future diabetic subjects are themselves above all the children of diabetic subjects. However, the prevalence of the disease among the descendants of type 2 diabetic subjects is around 20-30% and predictive tools are needed to combat diabetes in these high-risk families.
We propose to create a risk equation using an algorithm to reliably predict children most likely to develop diabetes later in life.
The algorithm will include 3 classes of data:
- The genotype stemming from the genetic characterization of individuals and those their parents;
- Environmental data concerning childhood, especially eating habits and physical activity;
- Data of the mother who was eventually diabetic during pregnancy.
From a methodological standpoint, it would be rather difficult to take blood samples from children and wait some 50 years to determine whether or not they develop diabetes. To circumvent this difficulty, we will recruit subjects in families with a history of type II diabetes:
- Parents alive, including at least one type 2 diabetic subject
- Adult children (aged over 35 years), some of whom are already presenting type II diabetes, and healthy brothers and sisters, who form the control population. Test will be done to determine whether healthy subjects are really safe from the risk of diabetes (HbA1c measurement and glucose load test).
The Descendence study will include 500 families at risk involving about 3000 subjects (1000 subjects with diabetes and 2000 healthy subjects). It is expected to answer the following question: for a child born in such families at risk, what is the probability of developing diabetes later in life, so that early preventive action may be taken
| Condition | Intervention |
|---|---|
|
Type 2 Diabetes |
Other: HbA1c measurement Other: Oral Glucoce Tolerance Test |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Prevention |
| Official Title: | Validation of a Predictive Risk Equation for Type 2 Diabetes in Children With Diabetes to Achieve a Predictive Diagnostic Biochip for the Early Detection of Individuals at Risk in Families. |
- Measure of risk of developing type 2 diabetes in at-risk families [ Time Frame: participants will be followed from the moment where they sign consent form and until they have sent back questionnary and done the blood test, an expected average of 4 weeks ] [ Designated as safety issue: No ]Oral Glucose Tolerance Test (only for health volunteers) HbA1c assay (for type 2 diabetic subject)
| Estimated Enrollment: | 3000 |
| Study Start Date: | December 2011 |
| Estimated Study Completion Date: | December 2013 |
| Estimated Primary Completion Date: | December 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Type 2 diabetic subject
Subject with type 2 diabetes
|
Other: HbA1c measurement |
|
healthy subject
Healthy subjet from family where there is the existence of the disease (type 2 diabetes) in two successive generations
|
Other: Oral Glucoce Tolerance Test
Oral Glucoce Tolerance Test
|
Eligibility| Ages Eligible for Study: | 35 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Families at risk for diabetes defined by the existence of the disease in two successive generations and consists with healthy subject in the two generations.
- Subjects must be aged over 35 years
Exclusion Criteria:
- subject refusing to participate
- pregnant women
Contacts and Locations| Contact: Guillaume CHARPENTIER, MD | +33164969599 |
| Belgium | |
| CHU Sart Tilman Liège | Recruiting |
| Liege, Belgium, 4000 | |
| Contact: Andre Scheen, MD PHD | |
| Sub-Investigator: Régis RADERMECKER, MD | |
| Principal Investigator: Andre Scheen, MD PHD | |
| France | |
| CHU Jean Minjoz | Recruiting |
| Besancon, France, 25030 | |
| Contact: Alfred PENFORNIS, MD PHD | |
| Principal Investigator: Alfred PENFORNIS, MD PHD | |
| Sub-Investigator: Annie CLERGEOT, MD | |
| CHU de Bondy | Recruiting |
| Bondy, France | |
| Contact: Emmanuel Cosson, MD PHD | |
| Principal Investigator: Emmanuel Cosson, MD PHD | |
| CHU de Caen | Recruiting |
| Caen, France, 14000 | |
| Contact: Yves REZNIK, MD | |
| Principal Investigator: Yves REZNIK, MD PHD | |
| Sub-Investigator: Michael JOUBERT, MD | |
| Sub-Investigator: Anne ROD, MD | |
| Sub-Investigator: Julia MORERA, MD | |
| CH Sud Francilien | Recruiting |
| Evry, France, 91000 | |
| Contact: Guillaume Charpentier, MD | |
| Principal Investigator: Guillaume CHARPENTIER, MD | |
| University Hospital Grenoble | Recruiting |
| Grenoble, France, 38043 | |
| Contact: Pierre Yves Benhamou, MD PhD | |
| Principal Investigator: Pierre Yves Benhamou, MD PhD | |
| CHRU Lille | Recruiting |
| Lille, France, 59037 | |
| Contact: Pierre Fontaine, MD PHD | |
| Principal Investigator: Anne WAMBERGUE, MD | |
| Principal Investigator: Pierre FONTAINE, MD PHD | |
| CHU Marseille Hôpitaux Sud | Recruiting |
| Marseille, France, 13274 | |
| Contact: Catherine Zevaco Mattei, MD | |
| Sub-Investigator: Pauline SCHAEPELYNCK-BELICAR, MD | |
| Principal Investigator: Catherine ZEVACO MATTEI, MD | |
| CHU de Nancy | Recruiting |
| Nancy, France, 54500 | |
| Contact: Bruno GUERCI, MD PHD | |
| Principal Investigator: Bruno GUERCI, MD PHD | |
| Centre Hospitalier Strasbourg | Recruiting |
| Strasbourg, France, 67000 | |
| Contact: Nathalie Jeandidier, MD PHD | |
| Sub-Investigator: Nathalie JEANDIDIER, MD PHD | |
| CHU Toulouse | Recruiting |
| Toulouse, France, 31403 | |
| Contact: Hélène Hanaire, MD PHD | |
| Principal Investigator: Hélène HANAIRE, MD | |
More Information
No publications provided
| Responsible Party: | Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète |
| ClinicalTrials.gov Identifier: | NCT01727349 History of Changes |
| Other Study ID Numbers: | 2011-A00686-35 |
| Study First Received: | November 8, 2012 |
| Last Updated: | November 12, 2012 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Additional relevant MeSH terms:
|
Diabetes Mellitus Diabetes Mellitus, Type 2 Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013